CTG PHARMA- SAFE CAR T THERAPY FOR SOLID TUMORS

Yoav Ben Ya'acov, CEO, CTG Pharma, Rehovot, Israel

- Investment Rational

CTG develops a biological solution to enable the use of CAR T therapy for the treatment of solid tumors

- Business Strategy

- Core Technology

In order to avoid the 'On-target/Off-tumor toxicity', the company builds a rationally designed library of 65K 'ON switches', for inducible expression of any CAR for the treatment of any type of cancer. The chosen ON switch ensures that the engineered T cells will target only tumor cells expressing the target antigen.

- Product Profile/Pipeline

The Proof Of Concept was achieved on Her2+ breast cancer. Yet, the platform is unlimited and potentially applicable to other types of cancer and CAR T therapies.

- What's Next?
  
  R&D
  Preclinical / Clinicals
  Organizational plans
  Financial plans